UK's Indivior to re-domicile to US after listing move

Core Viewpoint - Indivior plans to relocate its corporate domicile from the UK to the United States, establishing a new parent company based in Delaware [1] Company Summary - The decision to move to the US comes just months after the pharmaceutical firm made significant changes to its corporate structure [1] - This relocation is part of a broader strategy to enhance operational efficiency and align with market opportunities in the US [1] Industry Context - The pharmaceutical industry is witnessing a trend of companies relocating their headquarters to jurisdictions with more favorable regulatory environments and tax structures [1] - This move may reflect a growing preference among pharmaceutical firms to be closer to key markets and investors in the US [1]